Searched for
EMCURE PHARMACEUTICALS SHARE PRICE
Emcure Pharma shares jump 7% after Q2 profit rises 29% YoY to Rs 325 croreEmcure Pharmaceuticals shares rose up to 7.3% after the company reported a 29.3% year-on-year increase in Q2 FY27 profit to Rs 325.1 crore....- Stocks in news: ITC, Marico, SBI, Yatra Online, NSE, Container Corp and Sun PharmaIndian equity benchmarks experienced gains, with Nifty nearing the 23,500 resistance level and strong corporate earnings reported. ITC face...
- High Court restrains NPPA from action against AstraZenecaThe Delhi High Court has issued a temporary restraining order against the NPPA's actions toward AstraZeneca Pharma. This order remains in e...
- Market Trading Guide: Tata Steel among 5 stocks to buy on Tuesday for healthy returnsIndian equities experienced a strong start to the week, bolstered by better than expected Q2 earnings. Improved domestic macro indicators c...
- Weekly Top Picks: These stocks scored 10 on 10 on Stock Reports PlusStock Reports Plus, powered by Refinitiv, undertakes detailed company analysis for 4,000+ listed stocks. In addition to detailed company an...
- Mold-Tek Packaging shares surge 17% as Q2 FY 27 profit jumps 35% YoY to Rs 21 croreMold-Tek Packaging shares surged nearly 17% after the company reported a 35.5% YoY rise in Q2 FY27 net profit and 30.5% revenue growth. Str...
- Top Nifty50 stocks analysts suggest buying in this volatile weekStock Reports Plus, powered by Refinitiv, is a comprehensive report that evaluates five key components of 4,000+ listed stocks – earnings, ...
- Sun Pharma’s specialty portfolio, Organon deal to drive growthSun Pharmaceutical achieved notable revenue growth in the September quarter, driven by strong performance in India and specialty medicines....
- Two Trades for Today: A capital market stock for a 4.55% gain, a large-cap IT services company for a rise of about 7%Our technical analysts identify select stocks every trading day that may gain momentum even in volatile markets. Here are the technical cal...
- Short-term headwinds, yes; owning the ecosystem is better: 20 healthcare stocks with downside risk of 23% to upside potential of 41%The healthcare sector is under scrutiny. The issue is pricing: What medicines cost and on what hospitals and the rest of the health ecosyst...
- Time to be be cautious in the market, convinced about the business: 5 large-cap stocks with upside potential of up to 22%This is the time to focus on businesses that have lived through storms like this before and come out the other side. The large, proven name...
- Sun Pharma books Rs 346 crore Organon deal costs in Q2; profit falls 36%Sun Pharmaceutical Industries experienced a significant decline in net profit during the September quarter of FY27. The company incurred ac...
- NPPA list brings little relief: No price cut for 25% cancer drugsNearly one in four cancer drug packs in the NPPA’s revised price list will see no reduction in MRP, even as the overall average cut across ...
- These large-, mid- and small-cap stocks can give more than 20% return in 1 year, according to analystsHere’s one thing that is worth clarifying, because it is in the headlines. Large global technology companies have been announcing heavy spe...
- Weekly Top Picks: These stocks scored 10 on 10 on Stock Reports PlusStock Reports Plus, powered by Refinitiv, undertakes detailed company analysis for 4,000+ listed stocks. In addition to detailed company an...
- MFs raise stake for 3 straight quarters in 5 mid-cap stocks; shares gain up to 75% YTDMutual funds steadily increased their holdings in 39 BSE midcap stocks for three consecutive quarters through September 2026. While five st...
- Kotak adds 5 new midcap stocks which fell up to 16% in one month to its model portfolio. Take a lookIn response to recent market fluctuations, Kotak Institutional Equities has revamped its model portfolio, strategically introducing five mi...
- Forget short-term pressure; in the long term, the right business is what pays: 5 mid-cap stocks with an upside potential of up to 36%We have said this before, and we say it again: No one can predict when the market will bottom out. You can see the bottom only in hindsight...
- Cipla Q2 Results: Profit falls 35% YoY to Rs 878 crore; revenue slips 2%Cipla reported a 35% drop in consolidated net profit for Q2FY27, which stood at Rs 878 crore. The company also experienced a 2.4% year-on-y...
- Two Trades for Today: A top pharma company for a 6.3% upmove, a large-cap hospitality stock for a gain of almost 7%Our technical analysts identify select stocks every trading day that may gain momentum even in volatile markets. Here are the technical cal...
Load More
